Clinical Scorecard: Staging and Practical Management of Diabetic Retinopathy

At a Glance

Key Highlights

• The International Clinical Diabetic Retinopathy (ICDR) staging system classifies DR into nonproliferative (NPDR) and proliferative (PDR) stages.
• Diabetic macular edema (DME) can occur at any stage and is the leading cause of moderate vision loss in type 2 diabetes.
• High-risk PDR requires urgent referral to retina specialists for treatment to prevent blindness.

Guideline-Based Recommendations

Diagnosis

• Use dilated fundus examination to identify microaneurysms, hemorrhages, cotton wool spots, venous beading, IRMAs, and neovascularization.
• Fluorescein angiography (FA) is not indicated in early NPDR stages but useful to distinguish IRMAs from neovascularization in advanced stages.
• Optical coherence tomography (OCT) is essential for detecting and monitoring diabetic macular edema.

Management

• Repeat dilated eye exams at intervals based on DR severity: 1 year for mild NPDR, 6 months for moderate NPDR, 2-3 months for severe NPDR.
• Refer patients with severe or very severe NPDR and all PDR to retina specialists for consideration of panretinal photocoagulation (PRP) and/or intravitreal anti-VEGF injections.
• Refer patients with center-involved DME to retina specialists within 2 to 4 weeks; monitor non–center-involved DME every 3 to 4 months with OCT.

Monitoring & Follow-up

• Use color fundus photography for patient education and monitoring disease progression.
• Communicate findings to primary care providers to emphasize systemic disease management.
• Follow patients with moderate NPDR every 6 months, severe NPDR every 2 to 3 months, and PDR urgently as per risk.

Risks

• Approximately 5-10% of mild NPDR patients worsen within 1 year; up to 16% of moderate NPDR progress to PDR within 4 years.
• Half of severe NPDR and 75% of very severe NPDR progress to PDR within 1 year without treatment.
• Without treatment, 50% of PDR eyes become blind within 5 years.
• Rapid glycemic control improvement with GLP-1 receptor agonists like semaglutide may transiently worsen retinopathy but no long-term progression risk confirmed.

Patient & Prescribing Data

Patients with diabetes receiving GLP-1 receptor agonists, specifically semaglutide

Initial studies showed increased retinopathy rates and interventions with semaglutide; however, recent evidence suggests no increased long-term risk of retinopathy progression or vision loss.

Clinical Best Practices

• Accurately stage diabetic retinopathy using the ICDR system to guide follow-up intervals and referral timing.
• Evaluate all diabetic patients for diabetic macular edema with OCT regardless of retinopathy stage.
• Educate patients using color fundus photos to improve compliance with follow-up and systemic disease control.
• Coordinate care with primary care providers to optimize systemic diabetes management and reduce retinopathy progression risk.
• Refer high-risk and proliferative cases promptly to retina specialists for timely intervention.

References

• Early Treatment Diabetic Retinopathy Study (ETDRS) and ICDR staging
• SUSTAIN-6 Study on Semaglutide and Diabetic Retinopathy
• Stevens et al. Semaglutide and Retinopathy Progression Study